Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Belantamab + Dexamethasone + Pomalidomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Belantamab | GSK2857914|GSK-2857914|GSK 2857914 | TNFRSF17 Antibody 22 | Belantamab is a monoclonal antibody targeting TNFRSF17 (BCMA), which potentially decreases tumor growth (PMID: 34253590). | |
| Dexamethasone | Adexone | Desametasone | ||
| Pomalidomide | Pomalyst | CC-4047 | Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05714839 | Phase Ib/II | Belantamab + Belantamab mafodotin-blmf + Dexamethasone + Pomalidomide Belantamab Belantamab + Dexamethasone + Pomalidomide Belantamab mafodotin-blmf | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20) | Recruiting | USA | TUR | POL | GBR | BRA | AUS | ARG | 3 |